Myocardial ischaemic syndromes: a new nomenclature to harmonize evolving international clinical practice guidelines
William E Boden1, Raffaele De Caterina2, Juan Carlos Kaski3
1VA Boston Healthcare System, Boston University School of Medicine, 150 S. Huntington Avenue, Boston, MA 02130, USA.
Insights
New classifications for myocardial ischaemia aim to unify terminology, encompassing both obstructive and non-obstructive causes. This aims to improve diagnosis and treatment for conditions like chronic coronary syndromes and acute myocardial infarction.
Area of Science:
- Cardiology
- Medical Terminology
- Ischaemic Heart Disease
Background:
- Current classifications for chronic myocardial ischaemia use conflicting terms like 'stable coronary artery disease' (CAD) and 'chronic coronary syndromes' (CCS).
- Competing guidelines (European vs. American) have introduced divergent terminology, causing confusion.
- Existing terms like 'coronary' and 'disease' often narrowly focus on obstructive CAD, excluding other mechanisms.
Purpose of the Study:
- To propose a new, inclusive binary classification for myocardial ischaemia.
- To unify disparate nomenclatures across international guidelines.
- To foster conceptual clarity for both obstructive and non-obstructive causes of angina and myocardial ischaemia.
Main Methods:
- Proposed a binary classification: 'acute myocardial ischaemic syndromes' and 'non-acute myocardial ischaemic syndromes'.
- Included both obstructive epicardial and non-obstructive pathogenetic mechanisms (e.g., microvascular dysfunction, vasospastic disorders).
- Retained established categories of acute coronary syndromes (ACS) and myocardial infarction (MI) subtypes.
Main Results:
- The proposed classification encompasses a broader range of pathogenetic mechanisms.
- It includes conditions like ischaemia and MI with non-obstructive coronary arteries.
- The new nomenclature harmonizes different pathophysiologic causes of myocardial ischaemia.
Conclusions:
- The proposed classification offers a more encompassing nomenclature for myocardial ischaemia.
- It better aligns and unifies diagnostic and therapeutic approaches.
- This should lead to more refined treatments targeting diverse pathobiological precipitants of angina, ischaemia, and infarction.
Abstract:
Since the 1960s, cardiologists have adopted several binary classification systems for acute myocardial infarction (MI) that facilitated improved patient management. Conversely, for chronic stable manifestations of myocardial ischaemia, various classifications have emerged over time, often with conflicting terminology-e.g. 'stable coronary artery disease' (CAD), 'stable ischaemic heart disease', and 'chronic coronary syndromes' (CCS). While the 2019 European guidelines introduced CCS to impart symmetry with 'acute coronary syndromes' (ACS), the 2023 American guidelines endorsed the alternative term 'chronic coronary disease'. An unintended consequence of these competing classifications is perpetuation of the restrictive terms 'coronary' and 'disease', often connoting only a singular obstructive CAD mechanism. It is now important to advance a more broadly inclusive terminology for both obstructive and non-obstructive causes of angina and myocardial ischaemia that fosters conceptual clarity and unifies dyssynchronous nomenclatures across guidelines. We, therefore, propose a new binary classification of 'acute myocardial ischaemic syndromes' and 'non-acute myocardial ischaemic syndromes', which comprises both obstructive epicardial and non-obstructive pathogenetic mechanisms, including microvascular dysfunction, vasospastic disorders, and non-coronary causes. We herein retain accepted categories of ACS, ST-segment elevation MI, and non-ST-segment elevation MI, as important subsets for which revascularization is of proven clinical benefit, as well as new terms like ischaemia and MI with non-obstructive coronary arteries. Overall, such a more encompassing nomenclature better aligns, unifies, and harmonizes different pathophysiologic causes of myocardial ischaemia and should result in more refined diagnostic and therapeutic approaches targeted to the multiple pathobiological precipitants of angina pectoris, ischaemia and infarction.
Related Concept Videos
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Pathophysiology of Heart Failure
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System


